Companies & Industry »Company News»Company News Details
Company News Details


No Data Available
Code : 532321

NSE   27 Jan 15 | 03:31 PM

1651.40 4 (0.24%)
Mkt Price (Rs)   Chg Rs (Chg %)
1 Week : Rs 1,657.75 (-100.00%)
1 Month : Rs 1,575.10 (-100.00%)
1 Year : Rs 820.55 (-100.00%)
change companytradenow

Cadila's stock rising: Credit Suisse

Reuters / 18 Jul 12 | 11:50 AM

Credit Suisse initiates coverage on Cadila Healthcare with an "outperform" rating and a target price of Rs 970.

Investment bank says the midcap drug maker has demonstrated "strong execution" in the United States, with a portfolio mix focusing on low competition products such as nasal sprays and injectable drugs.

USFDA approval of its facilities in Moraiya, part of Gujarat, will re-start new approvals of its drugs in the US market, Credit Suisse adds.

"Cadila is moving up the value-chain with the launch of difficult-to formulate products and its strong execution record provides multi-year growth visibility."


Company Price Gain (%)
Axis Bank592.304.83
ICICI Bank383.703.58
HDFC Bank1,074.002.98

Online Portfolio

You can create Online Portfolio here using the below button.